Veracyte, Inc.

23.52 USD
-0.48 (-2.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Veracyte, Inc. stock is down -4.08% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 27.27% of the previous 10 March’s closed higher than February. 50% of analysts rate it a buy.

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas. It is also developing Percepta Genome Atlas to help inform lung cancer treatment decisions.

  • Morgan Stanley
    Mon Feb 26, 11:15
  • Needham
    Fri Feb 23, 05:33